Welgene Biotech Co.,Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 09, 2021
Share
Welgene Biotech Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 82.63 million compared to TWD 98.98 million a year ago. Net loss was TWD 0.103 million compared to net income of TWD 9.3 million a year ago.
For the nine months, sales was TWD 206.45 million compared to TWD 292.34 million a year ago. Net income was TWD 0.139 million compared to TWD 20.44 million a year ago. Basic earnings per share from continuing operations was TWD 0.01 compared to TWD 0.99 a year ago. Diluted earnings per share from continuing operations was TWD 0.01 compared to TWD 0.98 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
